Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Declines By 43.2%

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 8,400 shares, a drop of 43.2% from the October 31st total of 14,800 shares. Based on an average daily volume of 20,500 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.7% of the shares of the stock are sold short.

Xenetic Biosciences Price Performance

XBIO opened at $4.12 on Thursday. The firm has a market capitalization of $6.34 million, a P/E ratio of -1.55 and a beta of 2.25. Xenetic Biosciences has a one year low of $2.78 and a one year high of $5.20. The company has a fifty day moving average price of $3.92 and a 200-day moving average price of $3.92.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The company had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $0.75 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. On average, analysts expect that Xenetic Biosciences will post -1.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of Xenetic Biosciences in a report on Friday, November 22nd.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.